Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

unknown250%
terminated125%
not_yet_recruiting125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_1

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

NCT06199466
not_yet_recruitingphase_1

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

NCT06662669
unknownphase_1

YL-13027 in Patients With Advanced Solid Tumors

NCT05228600
unknownphase_1

First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

NCT03869632

Clinical Trials (4)

Showing 4 of 4 trials
NCT06199466Phase 1

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Terminated
NCT06662669Phase 1

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not Yet Recruiting
NCT05228600Phase 1

YL-13027 in Patients With Advanced Solid Tumors

Unknown
NCT03869632Phase 1

First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4